Centessa Pharmaceuticals plc
CNTA
$17.31
$1.237.65%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 76.52% | -161.54% | 2.85% | -15.17% | -3.28% |
| Total Depreciation and Amortization | 141.11% | 9.76% | -2.38% | -65.00% | 135.29% |
| Total Amortization of Deferred Charges | -- | -9.09% | 1.32% | -- | -- |
| Total Other Non-Cash Items | -83.52% | 384.15% | 0.33% | -8.36% | 7.87% |
| Change in Net Operating Assets | -252.67% | 109.21% | 304.73% | 35.89% | -166.51% |
| Cash from Operations | -33.75% | -100.10% | 47.29% | -8.83% | -20.08% |
| Capital Expenditure | -- | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -989.55% | -44.44% | 181.14% | -430.86% | 191.86% |
| Cash from Investing | -989.55% | -44.40% | 181.08% | -430.86% | 191.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 48.19% | -97.85% | 128.50% | 929.96% | 64.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -201.58% | -63.61% | 64.87% | -- | -- |
| Cash from Financing | 4.15% | -98.80% | 133.57% | 903.65% | 64.96% |
| Foreign Exchange rate Adjustments | -150.03% | 259.24% | -1,486.67% | -154.79% | 143.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,255.48% | -104.41% | 2,823.90% | 193.29% | 77.43% |